* Atrix Laboratories Inc., of Fort Collins, Colo., received an approvable letter from the FDA for Atridox, a product used in the treatment of periodontal disease. Following a decision on product labeling, Atrix expects FDA marketing approval. In addition, under terms of its North American marketing agreement with Block Drug Corp., in Jersey City, N.J., Atrix received a $7 million milestone payment.

* Introgen Therapeutics Inc., of Austin, Texas, said Oncormed Inc. of Gaithersburg, Md., will conduct p53 testing for Introgen's Phase I trials of its adenoviral p53 gene therapy. The testing will provide analysis of clinical tissue samples to expand the understanding of the p53 tumor suppressor gene's role in cancer.

No Comments